D.E. Shaw & Co’s Immune Design Corp. IMDZ Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q2 | – | Sell |
-257,007
| Closed | -$1.5M | – | 4044 |
|
|
2019
Q1 | $1.5M | Buy |
257,007
+51,859
| +25% | +$177K | ﹤0.01% | 2349 |
|
|
2018
Q4 | $267K | Buy |
205,148
+103,201
| +101% | +$179K | ﹤0.01% | 3415 |
|
|
2018
Q3 | $352K | Buy |
101,947
+83,777
| +461% | +$315K | ﹤0.01% | 3297 |
|
|
2018
Q2 | $83K | Sell |
18,170
-288
| -2% | -$1.15K | ﹤0.01% | 3626 |
|
|
2018
Q1 | $61K | Sell |
18,458
-76,559
| -81% | -$271K | ﹤0.01% | 3415 |
|
|
2017
Q4 | $371K | Buy |
95,017
+84,994
| +848% | +$463K | ﹤0.01% | 3143 |
|
|
2017
Q3 | $104K | Sell |
10,023
-10,099
| -50% | -$99.4K | ﹤0.01% | 3363 |
|
|
2017
Q2 | $196K | Sell |
20,122
-14,540
| -42% | -$102K | ﹤0.01% | 3198 |
|
|
2017
Q1 | $236K | Sell |
34,662
-14,518
| -30% | -$83.9K | ﹤0.01% | 3067 |
|
|
2016
Q4 | $270K | Buy |
+49,180
| New | +$347K | ﹤0.01% | 3156 |
|
|
2016
Q1 | – | Sell |
-10,659
| Closed | -$214K | – | 4110 |
|
|
2015
Q4 | $214K | Buy |
+10,659
| New | +$184K | ﹤0.01% | 3531 |
|
D.E. Shaw & Co's IMDZ Position: Q2 2019 in Review
D.E. Shaw & Co sold out of Immune Design Corp. (IMDZ) in Q2 2019, closing a stake of 257,007 shares — an estimated $1.5M sold.
D.E. Shaw & Co first reported a position in IMDZ in Q4 2015 and held it in 11 quarters. The position peaked at $1.5M in Q1 2019. 0 funds tracked by Wall St. Rank hold IMDZ as of Q2 2019.
- D.E. Shaw & Co reported no remaining Immune Design Corp. position as of Q2 2019 after selling out during the quarter.
- D.E. Shaw & Co sold 257,007 Immune Design Corp. shares in Q2 2019, an estimated $1.5M.
- D.E. Shaw & Co first reported a position in Immune Design Corp. in Q4 2015 and held it in 11 quarters.
- D.E. Shaw & Co's Immune Design Corp. position peaked at $1.5M in Q1 2019.
- 0 funds tracked by Wall St. Rank held Immune Design Corp. as of Q2 2019.
Based on D.E. Shaw & Co's 13F filing for Q2 2019, filed 14 Aug 2019.